Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation

Annals of Hematology

Volumn 86, Issue 5, 2007, Pages 355-361

  Ammatuna, Emanuele ^a   Ottone, Tiziana ^a   Zaza, Serena ^a   Lavorgna, Serena ^a   Grillo, Rosa ^a   Curzi, Paola ^a   Panetta, Paola ^a   Federici, Giorgio ^a,b,c   Amadori, Sergio ^a   Lo Coco, Francesco ^a,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Capillary electrophoresis; Chronic myeloproliferative syndromes; Jak2; Multiplex PCR; Thrombocytosis

Indexed keywords

BCR ABL PROTEIN; COMPLEMENTARY DNA; JANUS KINASE 2; RNA;

ADULT; AGED; ARTICLE; AUTOMATION; BLOOD CELL COUNT; BONE MARROW CELL; CAPILLARY ELECTROPHORESIS; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DNA SYNTHESIS; ERYTHROCYTOSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SEQUENCE ANALYSIS; THROMBOCYTHEMIA; THROMBOCYTOSIS;

DNA MUTATIONAL ANALYSIS; ELECTROPHORESIS, CAPILLARY; FUSION PROTEINS, BCR-ABL; GENES, ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; JANUS KINASE 2; MYELOPROLIFERATIVE DISORDERS; POLYMERASE CHAIN REACTION;

EID: 33947611005     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-007-0259-9     Document Type: Article

References (18)

1. O'Brien S, Tefferi A, Valent P (2004) Chronic myelogenous leukemia and myeloproliferative disease. Hematology Am Soc Hematol Educ Program, pp 146-162
2. Tefferi A, Gilliland DG (2005) The JAK2 (V617F) tyrosine kinase mutation in myeloproliferative disorders: Status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc 80:947-958
3. Sessarego M, Defferrari R, Dejana AM, Rebuttato AM, Fugazza G, Salvidio E et al (1989) Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation. A 12-year study. Cancer Genet Cytogenet 43:57-65
4. De Keersmaecker K, Cools J (2006) Chronic myeloproliferative disorders: a tyrosine kinase tale. Leukemia 20: 200-205
5. Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640-2653
6. Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302
7. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054-1061
8. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144-1148
9. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790
10. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397
11. Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V et al (2006) The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 108:1865-1867
12. Tefferi A, Gilliland DG (2005) The JAK2 (V617F) tyrosine kinase mutation in myeloproliferative disorders: Status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc 80:947-958
13. Schafer A (2004) Thrombocytosis. N Engl J Med 350:1211-1219
14. Chomczynsky P, Sacchi N (1987) Single step method of RNA isolation by acid guanidium thiocyanate phenol chloroform extraction. Anal Biochem 162:156-159
15. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: Investigation of minimal residual disease in acute leukemia. Leukemia 13:1901-1928
16. Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P et al (2006) X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 107:4139-4141
17. Tefferi A, Barbui T (2005) Bcr/abl-negative, classic myeloproliferative disorders: Diagnosis and treatment. Mayo Clin Proc 80:1220-1232
18. Murphy S, Peterson P, Iland H, Laszlo J (1997) Experience of the Polycythemia Vera Study Group with essential thrombocythemia: A final report on diagnostic criteria, survival and leukemic transition by treatment. Semin Hematol 34:29-39